A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

How are patient-centered solutions transforming breakthroughs in oncology and beyond?

by Chris Zant, life sciences digital leader and Brett J. Davis, general manager of ConvergeHEALTH

With National Cancer Prevention Month taking place this month, the Deloitte Center for Health Solutions (CHS) sat down with Chris Zant, life sciences digital leader, and Brett Davis, general manager of ConvergeHEALTH, to explore how digital technology, real-world data, and advanced analytics are helping lead to breakthrough therapies that are helping transform the journey of care for cancer patients,

Read more

The 21st century cures act one year later: Big ideas still needed

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

December 13 marked the one-year anniversary of the 21st Century Cures Act. While the law holds tremendous promise for enabling treatments and even cures for disease, multi-sector collaboration – and federal funding – is likely essential if the law is to reach its potential.

The three-year journey that culminated in the passage and enactment of the law was filled with idea generation and questions.

Read more

Open innovation could lead to a more sustainable health care ecosystem

by Kristin Feeney, Senior Data Scientist, ConvergeHEALTH by Deloitte, Deloitte Consulting LLP

The concept of open innovation extends to every industry, everywhere. Life sciences and health care organizations are no exception, and we are commonly seeing the impact of openness with respect to the explosion of electronic health care data across the ecosystem.

Open innovation can drive the agenda to harness a wealth of extensive network data to help propel innovation in the life sciences industry.

Read more

Real-world evidence: Four shifts ushering in a new era of evidence in life sciences and health care

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

How serious are life sciences companies about real-world evidence (RWE)? Very, according to our new benchmark survey focused solely on the life sciences industry’s investments in RWE. More than half (54 percent) of the organizations who participated in the interviews said they are investing significantly in their RWE programs to increase their capabilities.

Read more